M
Monika Lamba Saini
Researcher at Université catholique de Louvain
Publications - 12
Citations - 590
Monika Lamba Saini is an academic researcher from Université catholique de Louvain. The author has contributed to research in topics: Cancer & Lymphoma. The author has an hindex of 8, co-authored 12 publications receiving 484 citations.
Papers
More filters
Journal ArticleDOI
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer.
Kamal S Saini,Kamal S Saini,Sherene Loi,Evandro de Azambuja,Otto Metzger-Filho,Monika Lamba Saini,Michail Ignatiadis,Janet Dancey,Martine Piccart-Gebhart,Martine Piccart-Gebhart +9 more
TL;DR: A review of the current relevant pre-clinical and clinical data is presented and the rationale for dual inhibition of these pathways in the treatment of BC patients is discussed.
Journal ArticleDOI
Effect of the COVID-19 pandemic on cancer treatment and research.
Kamal S Saini,Kamal S Saini,Begoña de las Heras,Javier de Castro,Ramachandran Venkitaraman,Martine Poelman,Gopalakrishnan Srinivasan,Monika Lamba Saini,Sanjeev Verma,Manuela Leone,Philippe Aftimos,Giuseppe Curigliano +11 more
Journal ArticleDOI
Rituximab in Hodgkin lymphoma: Is the target always a hit?
Kamal S Saini,Hatem A. Azim,Emilia Cocorocchio,Anna Vanazzi,Monika Lamba Saini,Paola Rafaniello Raviele,Giancarlo Pruneri,Fedro A. Peccatori +7 more
TL;DR: A clinically-oriented overview of the use of rituximab in the different sub-types of HL, and report updated results of the series of 8 LPHL patients treated with ritUXimab.
Journal ArticleDOI
Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy.
Kamal S Saini,Kamal S Saini,Carlo Lanza,Marco Romano,Evandro de Azambuja,Evandro de Azambuja,Javier Cortes,Begoña de las Heras,Javier de Castro,Monika Lamba Saini,Sibylle Loibl,Giuseppe Curigliano,Chris Twelves,Manuela Leone,Mrinal M. Patnaik +14 more
TL;DR: Three cardinal manifestations of neoplasia, namely inflammation, immune dysfunction, and coagulopathy are also seen in patients with severe SARS-CoV-2 infection, providing a biological rationale for testing selected anticancer drugs for their ability to control the symptoms and/or modify the course of COVID-19.
Journal ArticleDOI
Cancer Treatment and Research During the COVID-19 Pandemic: Experience of the First 6 Months.
Begoña de las Heras,Kamal S Saini,Kamal S Saini,Frances M. Boyle,Felipe Ades,Evandro de Azambuja,Evandro de Azambuja,Ivana Bozovic-Spasojevic,Marco Romano,Marta Capelán,Rajeev Prasad,Pugazhenthi Pattu,Christophe Massard,Chia Portera,Monika Lamba Saini,Brajendra Prasad Singh,Ramachandran Venkitaraman,Richard J. Q. McNally,Manuela Leone,Enrique Grande,Sudeep Gupta +20 more
TL;DR: The coronavirus disease-2019 (COVID-19) pandemic has had a significant impact on patients with underlying malignancy and patients with malignancies are likely to be more vulnerable than the general population to contracting CO VID-19.